GlassScriptPhysician profile
Patricia L Doolin
NPI 1427549559
$2,478.35
in general payments reported to CMS, 2019-2025
23 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $65.28 · 2023: $197 · 2024: $462 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $470.55 | 2022-2025 | Auvelity |
| Abbvie INC. | $407.06 | 2021-2025 | |
| Alkermes, INC. | $365.15 | 2024-2025 | Lybalvi, Aristada |
| Astrazeneca Pharmaceuticals LP | $225.65 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Vanda Pharmaceuticals INC. | $182.26 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.21 | 2022-2025 | Caplyta |
| Pfizer INC. | $103.18 | 2023-2024 | |
| Amgen INC. | $93.67 | 2024-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $93.38 | 2023-2025 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $67.27 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $51.83 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.44 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $49.70 | 2021-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $27.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.06 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $21.92 | 2023 | Qutenza |
| Optinose US, INC. | $19.02 | 2024 | |
| Cipher Pharmaceuticals US LLC | $16.74 | 2025 | Natroba, Spinosad |
| Idorsia Pharmaceuticals US INC | $15.02 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $14.98 | 2022 | |
| Astellas Pharma US INC | $14.67 | 2024 | Veozah |
| Lundbeck LLC | $14.09 | 2025 | Rexulti |
| Genentech USA, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Doolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.